---
title: üèõÔ∏è Reagan‚ÄìUdall Foundation
description: An independent nonprofit organization created by Congress to advance regulatory science and modernize the FDA
published: true
date: 2025-05-28T22:17:00.000Z
tags: nonprofit, fda, regulatory-science, healthcare-policy
editor: markdown
dateCreated: 2025-05-28T22:17:00.000Z
---

# Reagan‚ÄìUdall Foundation

## Overview

Established by Congress in 2007, the Reagan‚ÄìUdall Foundation is an independent nonprofit organization that works in partnership with the FDA to modernize regulatory science and improve the regulatory process for medical products.

## Key Initiatives

- Conducts independent evaluations of FDA programs
- Advances the use of real-world evidence in regulatory decision-making
- Develops tools and resources to facilitate expanded access to investigational treatments

## Impact

- Dozens of recommendations adopted by the FDA
- Improved trial data transparency and regulatory processes
- Development of the Expanded Access Navigator used by patients and physicians

## Scale

- **Assets:** $6.4 million
- **Annual Revenue:** $8.33 million
- **Funding Sources:** Mix of FDA grants, industry contracts, and donations

## Community & Partnerships

- Receives approximately $1.65 million annually in FDA funding
- Collaborates with industry and academic institutions
- Board includes FDA officials (ex officio) and industry representatives
- Works with patient advocacy groups like Friends of Cancer Research

## Notable Projects

- **Expanded Access Navigator:** Guides patients and doctors through the compassionate use process
- **Evidence Accelerator:** Facilitates COVID-19 real-world data collaboration
- Regulatory science fellowship programs
- Independent expert panel reports that inform FDA policy

## Alignment with dFDA

- **Alignment Level:** Moderate
- Focused on modernizing and improving the FDA rather than decentralizing it
- Strong credibility and access to FDA leadership
- Potential for implementing pilot programs within the existing regulatory framework

## Strategic Considerations

- **Strengths:** Quasi-governmental status, direct FDA connections, policy influence
- **Challenges:** Unlikely to support initiatives that would significantly reduce FDA authority

## Learn More

- [Official Website](https://reaganudall.org/)
- [Expanded Access Navigator](https://navigator.reaganudall.org/)

*Last updated: May 2025*
